Positive news for Pfizer's top-selling drug that could delay competition

12 October 2017

US pharma giant Pfizer (NYSE: PFE) received good news today, when the US Food and Drug Administration granted approval for a new formulation of its top-selling drug Lyrica (pregabalin), which in December next year is facing patent expiry.

The US FDA has approved Lyrica extended-release tablets CV as once-daily therapy for the management of neuropathic pain associated with diabetic peripheral neuropathy (pDPN) and the management of postherpetic neuralgia (PHN). However, Lyrica CR did not receive approval for the management of fibromyalgia, which is the drug’s original indication.

If physicians switch patients to the new formulation, this is a regulatory decision that could fend off generic competition a little longer for Lyrica, which last year generated sales of $3.13 billion in the USA alone, a 26% year-on-year rise, but the news had virtually no impact on Pfizer’s shares

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK